Mylan Turns To Meda In Sweden For Open Door Into Consumer Market
This article was originally published in The Tan Sheet & The Rose Sheet
The deal is subject to 90% of Meda shareholders tendering shares, and the two largest shareholders, accounting for about 30% of shares, already committed to the deal. Mylan will pay around $8.5bn in cash and debt and about $1.4bn in stock.
You may also be interested in...
Meda Consumer Healthcare is relaunching the Feosol iron supplement brand with three SKUs and aims to become the clear No. 1 brand in the category. Meda’s Swedish parent company prioritizes OTC growth through brand acquisitions and increased marketing resources.
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.
Under Senate legislation proposing mandatory listing with FDA for all supplements sold in US, a product labeled in compliance with all other agency regulations would be deemed misbranded if not registered for proposed list.